rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2018-429-432rsp-2587Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL RESEARCHМесто стронция ранелата в лечении больных остеопорозом (результаты программы МАРК)THE PLACE OF STRONTIUM RANELATE IN THE TREATMENT OF PATIENTS WITH OSTEOPOROSIS (RESULTS OF THE MARC PROGRAM)НикитинскаяО. А.NikitinskayaO. A.nikitinskayaox@yandex.ruТоропцоваН. В.ToroptsovaN. V.НасоновЕ. Л.NasonovE. L.

кафедра ревматологии Института профессионального образования

Department of Rheumatology, Institute of ProfessionalEducation

ФГБУ «Научноисследовательский институт ревматологии им. В.А. Насоновой», МоскваРоссияV.A. Nasonova Research Institute of Rheumatology, MoscowRussian FederationФГБУ «Научноисследовательский институт ревматологии им. В.А. Насоновой», Москва; ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияV.A. Nasonova Research Institute of Rheumatology, Moscow; I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaRussian Federation201808092018564429432Copyright © Никитинская О.А., Торопцова Н.В., Насонов Е.Л., 20182018Никитинская О.А., Торопцова Н.В., Насонов Е.Л.Nikitinskaya O.A., Toroptsova N.V., Nasonov E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2587

Препарат стронция ранелат (СР), имеющий доказанную эффективность в отношении снижения риска переломов и повышения минеральной плотности костей, в настоящее время рекомендован для лечения тяжелого остеопороза (ОП) у женщин в постменопаузе и пожилых мужчин как препарат второго выбора. Материал и методы. В 2014–2015 гг. в рамках программы МАРК (приМенение Антиостеопоротических препаратов в Реальной Клинической практике) проведено анкетирование 1799 больных ОП (от 25 до 92 лет), получавших не менее года терапию по поводу этого заболевания. Среди опрошенных было 1696 человек в возрасте 50 лет и старше (средний возраст – 64±7 лет; длительность болезни – 2,7±2,4 года): 86% женщин и 14% мужчин, которые и стали объектом данного исследования. Приверженность проводимой антиостеопоротической терапии оценивалась за последние 12 мес до анкетирования по следующим параметрам: какой препарат принимал, количество принятых упаковок, пропуски в лечении и соблюдение режима приема. Результаты и обсуждение. Анкетирование включенных в исследование пациентов показало, что 19% из них получали СР когда-либо на протяжении болезни, а 8% принимали его в течение года, предшествовавшего опросу. Таким образом, СР остается востребованным препаратом в реальной клинической практике для лечения тяжелого ОП у больных, не имеющих в анамнезе ишемической болезни сердца, неконтролируемой артериальной гипертензии, цереброваскулярных заболеваний, патологии периферических артерий, склонности к тромбозам и тромбоэмболиям.

Strontium ranelate (SR) that has a proven efficacy in reducing the risk of fractures and in increasing bone mineral density is currently recommended as a second choice drug for the treatment of severe osteoporosis (OP) in postmenopausal women and elderly men. Subjects and methods. In 2014–2015, a survey within the framework of the MARC program (The Use of Antiosteoporotic Drugs in Real Clinical Practice) was conducted in 1799 OP patients aged 25 to 92 years, who had been treated for this disease for at least one year. Among the respondents, there were 1696 people aged 50 years and older (mean age, 64±7 years; disease duration, 2.7±2.4 years) (86% women and 14% men) who were the subjects of this survey. Adherence to performed antiosteoporotic therapy was evaluated within the last 12 months before the survey by the following parameters: which drug had been taken; the number of packages used, treatment gaps and compliance with the treatment regimen. Results and discussion. The survey of the patients included in the study showed that 19% of them had received SR at any time over the course of the disease, and 8% had taken the drug within the year preceding the survey. Thus, SR remains a popular drug in real clinical practice for the treatment of severe OP in patients with no history of coronary heart disease, uncontrolled hypertension, cerebrovascular diseases, peripheral artery disease, and a predisposition to thrombosis and thromboembolism.

остеопорозстронция ранелатклиническая практикаosteoporosisstrontium ranelateclinical practiceReferencesBonnelye E, Chabadel A, Saltel F, Jurdic P. Dual effect of strontium ranelate: Stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone. 2008;42(1):129-38. doi: 10.1016/j.bone.2007.08.043Bonnelye E, Chabadel A, Saltel F, Jurdic P. Dual effect of strontium ranelate: Stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone. 2008;42(1):129-38. doi: 10.1016/j.bone.2007.08.043Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004;350(5):459-68. doi: 10.1056/NEJMoa022436Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004;350(5):459-68. doi: 10.1056/NEJMoa022436Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of non vertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab. 2005;90(5):2816-22. doi: 10.1210/jc.2004-1774Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of non vertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab. 2005;90(5):2816-22. doi: 10.1210/jc.2004-1774Kaufman JM, Audran M, Bianchi G, et al. Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men. J Clin Endocrinol Metab. 2013;98(2):592-601. doi: 10.1210/jc.2012-3048Kaufman JM, Audran M, Bianchi G, et al. Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men. J Clin Endocrinol Metab. 2013;98(2):592-601. doi: 10.1210/jc.2012-3048Reginster JY, Kaufman JM, Devogelaer JP, et al. Long-term efficacy and safety of strontium ranelate in postmenopausal osteoporotic women: results over 10 years. Osteoporos Int. 2011;22(S1):110-1.Reginster JY, Kaufman JM, Devogelaer JP, et al. Long-term efficacy and safety of strontium ranelate in postmenopausal osteoporotic women: results over 10 years. Osteoporos Int. 2011;22(S1):110-1.European Medicines Agency. PSUR assessment report – strontium ranelate. 2013. Available from: www.ema.europa.euEuropean Medicines Agency. PSUR assessment report – strontium ranelate. 2013. Available from: www.ema.europa.euCooper C, Fox KM, Borer JS. Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: a nested case–control study in the CPRD. Osteoporos Int. 2014;25:737-45. doi: 10.1007/s00198-013-2582-4Cooper C, Fox KM, Borer JS. Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: a nested case–control study in the CPRD. Osteoporos Int. 2014;25:737-45. doi: 10.1007/s00198-013-2582-4Abrahamsen B, Grove EL, Vestergaard P. Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with stronium ranelate. Osteoporos Int. 2014 Feb;25(2):757-62. doi: 10.1007/s00198-013-2469-4Abrahamsen B, Grove EL, Vestergaard P. Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with stronium ranelate. Osteoporos Int. 2014 Feb;25(2):757-62. doi: 10.1007/s00198-013-2469-4Audran M, Jakob FJ, Palacios S, et al. A large prospective European cohort study of patients treated with strontium ranelate and followed up over 3 years. Rheumatol Int. 2013;33(9):2231-9. doi: 10.1007/s00296-012-2594-yAudran M, Jakob FJ, Palacios S, et al. A large prospective European cohort study of patients treated with strontium ranelate and followed up over 3 years. Rheumatol Int. 2013;33(9):2231-9. doi: 10.1007/s00296-012-2594-yDonneau AF, Reginster JY. Cardiovascular safety of strontium ranelate: real-life assessment in clinical practice. Osteoporos Int. 2014 Feb;25(2):397-8. doi: 10.1007/s00198-013-2583-3Donneau AF, Reginster JY. Cardiovascular safety of strontium ranelate: real-life assessment in clinical practice. Osteoporos Int. 2014 Feb;25(2):397-8. doi: 10.1007/s00198-013-2583-3Nikitinskaya OA, Toroptsova NV, Feclistov AYu, Demin NV. Treatment of patients with osteoporosis in clinical practice: the issues of diagnostics and treatment. Lechashchij Vrach. 2016;(12):31-3 (In Russ.)Nikitinskaya OA, Toroptsova NV, Feclistov AYu, Demin NV. Treatment of patients with osteoporosis in clinical practice: the issues of diagnostics and treatment. Lechashchij Vrach. 2016;(12):31-3 (In Russ.)

The authors declare that there are no conflicts of interest present.